Program
Interleukin 1 Receptor Antagonist Protein
Also written as “Anakinra”, “Anakinra (Kineret®)” and “anakinra”.
Its studies are mostly in Arthritis, Rheumatoid · Arthritis, Juvenile · Familial Mediterranean Fever · COVID-19 · Still's Disease, Adult-Onset, led by 3 companies.
Drug pageInterleukin 1 Receptor Antagonist Protein: every studyAll 168 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgenits history only | 70 open or running | phase 4since May 20, 2005 | May 17, 2002 | none ahead |
| Swedish Orphan Biovitrum | 61 open or running | phase 4since Oct 8, 2024 | Dec 13, 2016 | none ahead |
| Hamad Medicalits history only | 10 open or running | phase 3since Nov 24, 2020 | Nov 24, 2020 | none ahead |
Also a collaborator on its studies: Tigermed Consulting and CMIC Co, Ltd. Japan.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Swedish Orphan Biovitrum only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 13, 2016First study: phase 2 study in GoutFirst studyNCT03002974 · 165 enrolled · United States
- Aug 25, 2017Phase 3 study in Still's Disease, Adult-OnsetNCT03265132 · 13 enrolled · United States, Canada
- Mar 25, 2020Phase 3 study in SARS-CoV-2NCT04324021 · 16 enrolled · United States, Italy
- Nov 22, 2022Phase 3 study in Arthritis, JuvenileNCT05814159 · 15 enrolled · Japan
- Oct 8, 2024Phase 4 study in Familial Mediterranean FeverNCT06666335
- Jun 24, 2026Phase 4 study in Arthritis, JuvenileNCT07706868
TargetBeta
“A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist ”NCIt, by rule
Other programs on IL1A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lutikizumab | AbbVie | phase 3 | 12 |
| ABBV-1451 | AbbVie | phase 1 | 1 |
Studies
All 6 Swedish Orphan Biovitrum leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07706868Arthritis, Juvenile | 4 | Withdrawn | Sep 30, 2028 | 0 |
| NCT06666335Familial Mediterranean Fever | 4 | Withdrawn | Aug 30, 2027 | 0 |
| NCT05814159Arthritis, Juvenile · Japan | 3 | Active, not recruiting | Dec 10, 2025 | 15 |
| NCT04324021SARS-CoV-2 · United States, Italy | 3 | Terminated | Nov 13, 2020 | 16 |
| NCT03265132Still's Disease, Adult-Onset · United States, Canada | 3 | Terminated | Feb 13, 2019 | 13 |
| NCT03002974Gout · United States | 2 | Completed | Jun 2018 | 165 |
How it is read
Names in the registry
- “Anakinra”, 5 entries
- “Anakinra (Kineret®)”, 2 entries
- “anakinra”, 2 entries
- “AMG 719”, 2 entries
- “Anakinra 100 mg”, 1 entry
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 5 studies
- Arthritis, Juvenile, 3 studies
- Familial Mediterranean Fever, 1 study
- COVID-19, 1 study
- Still's Disease, Adult-Onset, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.